Health Care · Pharmaceuticals
Bristol Myers Squibb: revenue, profit and dividends
In fiscal 2025, Bristol Myers Squibb had revenue of $48.2B, up 11.3% a year on average since 2015, and net income of $7.05B (14.6% of revenue). Its dividend per share has gone up 18 years in a row, to $2.49. It has 21% more shares than in 2015.
Revenue, fiscal 2025
average annual revenue growth since 2015 · −0.2% vs 2024
- Ticker
- BMY · NYSE
- Sector
- Health Care
- Sub-industry
- Pharmaceuticals
- Headquarters
- New York City, New York
- Founded
- 1989 (1887)
- In the S&P 500 since
- March 4, 1957, the index’s first day
- Latest fiscal year
- 2025, ended December 31, 2025
- SEC filer
- Bristol Myers Squibb Co · CIK 0000014272
Revenue and net income
Revenue went from $15.6B in 2007 to $48.2B in 2025. Net loss in 2020, 2024.
Diluted earnings per share
Diluted EPS went from $1.09 in 2007 to $3.46 in 2025. Ten-year growth: 14.0% a year.
Dividends per share
Raised every year in the data: 18 years in a row, from 2008 to 2025. Ten-year growth: 5.3% a year.
Shares outstanding
21.4% more shares in 2025 than in 2015 (1.68B → 2.04B): new shares outweighed buybacks.
Operating cash flow, capex and free cash flow
Free cash flow (operating cash flow minus capital expenditure) was $12.8B in 2025, 26.7% of revenue.
The chart data could not be loaded. The table below has the same figures.
Year by year
| Fiscal year | Revenue | Net income | Net margin | Diluted EPS | Dividend | Shares | Operating cash flow | Capex | Free cash flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | $48.2B | $7.05B | 14.6% | $3.46 | $2.49 | 2.04B | $14.2B | $1.31B | $12.8B |
| 2024 | $48.3B | −$8.95B | −18.5% | −$4.41 | $2.42 | 2.03B | $15.2B | $1.25B | $13.9B |
| 2023 | $45B | $8.03B | 17.8% | $3.86 | $2.31 | 2.08B | $13.9B | $1.21B | $12.7B |
| 2022 | $46.2B | $6.33B | 13.7% | $2.95 | $2.19 | 2.15B | $13.1B | $1.12B | $11.9B |
| 2021 | $46.4B | $6.99B | 15.1% | $3.12 | $2.01 | 2.25B | $16.2B | $973M | $15.2B |
| 2020 | $42.5B | −$9.02B | −21.2% | −$3.99 | $1.84 | 2.26B | $14.1B | $753M | $13.3B |
| 2019 | $26.1B | $3.44B | 13.2% | $2.01 | $1.68 | 1.71B | $8.21B | $836M | $7.37B |
| 2018 | $22.6B | $4.92B | 21.8% | $3.01 | $1.61 | 1.64B | $7.07B | $951M | $6.12B |
| 2017 | $20.8B | $1.01B | 4.8% | $0.61 | $1.57 | 1.65B | $5.28B | $1.05B | $4.22B |
| 2016 | $19.4B | $4.46B | 22.9% | $2.65 | $1.53 | 1.68B | $3.06B | $1.22B | $1.84B |
| 2015 | $16.6B | $1.56B | 9.5% | $0.93 | $1.49 | 1.68B | $2.1B | $820M | $1.28B |
| 2014 | $15.9B | $2.0B | 12.6% | $1.20 | $1.45 | 1.67B | $3.15B | $526M | $2.62B |
| 2013 | $16.4B | $2.56B | 15.6% | $1.54 | $1.41 | 1.66B | $3.54B | $537M | $3.01B |
| 2012 | $17.6B | $1.96B | 11.1% | $1.16 | $1.37 | 1.69B | $6.94B | $548M | $6.39B |
| 2011 | $21.2B | $3.71B | 17.5% | $2.16 | $1.33 | 1.72B | $4.84B | $367M | $4.47B |
| 2010 | $19.5B | $3.1B | 15.9% | $1.79 | $1.29 | 1.73B | $4.49B | $424M | $4.07B |
| 2009 | $18.8B | $10.6B | 56.4% | $5.34 | $1.25 | 1.98B | $4.07B | $730M | $3.33B |
| 2008 | $17.7B | $5.25B | 29.6% | $2.62 | $1.24 | — | $3.71B | $941M | $2.77B |
| 2007 | $15.6B | $2.17B | 13.9% | $1.09 | $1.15 | — | $3.15B | $843M | $2.31B |
Fiscal years, labelled by the year in which they end. US dollars; per-share figures and share counts adjusted for splits. —: not in the data.
About these figures
- Older years are as filed at the time and may predate later restatements, mergers or spin-offs. How the figures are made.
Other Pharmaceuticals companies
Source: SEC EDGAR (company filings), data as of November 8, 2026. Sectors, sub-industries, headquarters and index dates: Wikipedia, CC BY-SA 4.0.